(Albany, United States) As per DelveInsight’s assessment, globally, the Anaplastic Astrocytoma Pipeline constitutes 15+ key companies continuously working towards developing 15+ Anaplastic Astrocytoma Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Anaplastic Astrocytoma Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Anaplastic Astrocytoma NDA approvals (if any), and product development activities comprising the technology, Anaplastic Astrocytoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

To explore more information on the latest breakthroughs in the Anaplastic Astrocytoma Pipeline treatment landscape of the report, click here @ Anaplastic Astrocytoma Pipeline Outlook

 

Key Takeaways from the Anaplastic Astrocytoma Pipeline Report

• DelveInsight’s Anaplastic Astrocytoma Pipeline analysis depicts a robust space with 15+ active players working to develop 15+ pipeline treatment therapies.
• The leading companies working in the Anaplastic Astrocytoma Market include Orbus Therapeutics, Cothera Bioscience, Celgene, Wayshine Biopharm, Inc., OncoSynergy, AEterna Zentaris, Oncoceutics, DNAtrix, Novartis Pharmaceuticals, Curis, Inc., Everfront Biotech Co., Ltd., Pfizer, Kazia Therapeutics Limited, Bayer, Geneos Therapeutics, Cellix Bio, Mustang Bio, Deciphera Pharmaceuticals, Aveta Biomics, and others.
• Promising Anaplastic Astrocytoma Pipeline Therapies in the various stages of development include Eflornithine, Lomustine, Erlotinib, Sunitinib Malate, leflunomide, LS11 (talaporfin sodium), and others.
• On June 2023, Celgene announced a study of phase 1 clinical trials for CC-90010. CC-90010-GBM-001 is a multi-center, open-label study to assess the pharmacokinetics (PK), pharmacodynamics (PD) and CNS penetration of CC-90010 following short-term interval therapy (4 daily doses ) prior to surgery, in subjects with progressive or recurrent WHO Grade II Diffuse Astrocytoma, Grade III Anaplastic Astrocytoma and recurrent Glioblastoma who have failed radiation and chemotherapy, and who are candidates for surgical tumor resection as part of their salvage regimen (planned salvage resection).
• On June 2023, TVAX Biomedical announced a study of phase 1 & 2 clinical trials for Cancer vaccine plus immune adjuvant. TVI-Brain-1 is an experimental treatment that takes advantage of the fact that your body can produce immune cells, called ‘killer’ white blood cells that have the ability to kill large numbers of the cancer cells that are present in your body. TVI-Brain-1 is designed to generate large numbers of those ‘killer’ white blood cells and to deliver those cells into your body so that they can kill your cancer cells.

 

Anaplastic Astrocytoma Overview

Anaplastic Astrocytoma is a rare malignant brain tumor. Astrocytomas are tumors that develop from certain star-shaped brain cells called astrocytes.

 

For further information, refer to the detailed Anaplastic Astrocytoma Unmet Needs, click here for Anaplastic Astrocytoma Ongoing Clinical Trial Analysis

 

Anaplastic Astrocytoma Emerging Drugs Profile

 

• Eflornithine: Orbus Therapeutics

Eflornithine, also known as α-diflurormethylornithine (DFMO), selectively targets and irreversibly inhibits ornithine decarboxylase (ODC), an enzyme essential for polyamine synthesis, and DNA and RNA function. Unlike multi-targeted tyrosine kinase inhibitors on the market or in development, eflornithine targets only one specific enzyme, ODC. In animal studies, eflornithine has been shown to inhibit the growth of malignant tumors, including intra cerebral mid- and high-grade gliomas. Eflornithine administration has also been shown to potentiate the anti-tumor activity of other chemotherapy agents. In single-arm and controlled, randomized clinical trials, eflornithine oral solution increased survival in patients with both newly diagnosed and recurrent anaplastic glioma. The primary and reversible side effects of eflornithine were diarrhea and hearing impairment.

 

• Zotiraciclib: Cothera Bioscience

Zotiraciclib is a potent oral spectrum selective kinase inhibitor for the treatment of cancer. It was discovered in Singapore by S*BIO Pte Ltd and falls under the category of small molecule macrocycles. It crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9. In October 2021, Cothera Bioscience Inc. and Adastra Pharmaceuticals Inc., announced a definitive agreement under which Cothera has acquired zotiraciclib (ZTR).

 

Anaplastic Astrocytoma Pipeline Therapeutics Assessment

There are approx. 15+ key companies which are developing the therapies for Anaplastic Astrocytoma. The companies which have their Anaplastic Astrocytoma drug candidates in the most advanced stage, i.e. phase III include, Orbus Therapeutics.

 

Request a sample and discover the recent advances in Anaplastic Astrocytoma Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Anaplastic Astrocytoma Segmentation

 

Anaplastic Astrocytoma Drug and Companies

• Eflornithine: Orbus Therapeutics
• Erlotinib: Genentech Inc.
• Sunitinib Malate: Pfizer

 

Anaplastic Astrocytoma Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Anaplastic Astrocytoma Therapeutics Market include-

Orbus Therapeutics, Cothera Bioscience, Celgene, Wayshine Biopharm, Inc., OncoSynergy, AEterna Zentaris, Oncoceutics, DNAtrix, Novartis Pharmaceuticals, Curis, Inc., Everfront Biotech Co., Ltd., Pfizer, Kazia Therapeutics Limited, Bayer, Geneos Therapeutics, Cellix Bio, Mustang Bio, Deciphera Pharmaceuticals, Aveta Biomics, and others.

 

Dive deep into rich insights for drugs for Anaplastic Astrocytoma Pipeline, click here @ Anaplastic Astrocytoma Unmet Needs and Analyst Views

 

Scope of the Anaplastic Astrocytoma Pipeline Report

• Coverage- Global
• Companies- Orbus Therapeutics, Cothera Bioscience, Celgene, Wayshine Biopharm, Inc., OncoSynergy, AEterna Zentaris, Oncoceutics, DNAtrix, Novartis Pharmaceuticals, Curis, Inc., Everfront Biotech Co., Ltd., Pfizer, Kazia Therapeutics Limited, Bayer, Geneos Therapeutics, Cellix Bio, Mustang Bio, Deciphera Pharmaceuticals, Aveta Biomics, and others.
• Therapies- Eflornithine, Lomustine, Erlotinib, Sunitinib Malate, leflunomide, LS11 (talaporfin sodium), and others.
• Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Anaplastic Astrocytoma Merger and acquisitions, Licensing Activities

 

Table of Content

1. Introduction
2. Executive Summary
3. Anaplastic astrocytoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Anaplastic astrocytoma – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Eflornithine: Orbus Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug name: Company name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. GT-10: Geneos Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. CLX-ONC-643: Cellix Bio
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Anaplastic astrocytoma Key Companies
21. Anaplastic astrocytoma Key Products
22. Anaplastic astrocytoma- Unmet Needs
23. Anaplastic astrocytoma- Market Drivers and Barriers
24. Anaplastic astrocytoma- Future Perspectives and Conclusion
25. Anaplastic astrocytoma Analyst Views
26. Anaplastic astrocytoma Key Companies
27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services